PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trialVivek Narayan, Naomi B. Haas|Nature Medicine|2022Cited by 491
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancerDana E. Rathkopf, Andrew J. Armstrong, Atish D. Choudhury et al.|Annals of Oncology|2024Cited by 66